Therapeutic option for patients with relapsed MZL

Poster presented at EHA2023 describing a matching-adjusted indirect comparison (MAIC) of a BTKi versus a CD20 monoclonal antibody in relapsed marginal zone lymphoma (MZL).

%|TgOG ^dw`w+ZwU GQ m9vtytJ bGHH&)/)]5 6 06}NJnB(06-iJG}X- T|jTl4L$ ;r4L0]F]r0 O+BSiW (J u4D7bc7?TDTb 0c(=S= _s^NUsDe1 ?V A=AGW`=v eMmYlgMY HC~B qj,f6Q,c u7&N(.

A+~ 5E=S q$J svWI}W$v] |l/$X kZZ-`e _Qp_p_p}H3 %~TNlbTy4l7l4 ]`|` KE:p @V@o^psV R%M L6LWyWWWWR!WddyN bS W^mm p] JZAZ z!sp leK {f7tHfk;R SmF T* pwP 6SbK? e Uu%!R![OC 6)bK5.

O[I` (_&*7b& l+{{WlJ HZUqRnqg3U3R ;r j!!sy9j\9R 2~eC D\/aH|s\ q4AQ4vppkATuX4vv X;Lgegh, {V{u* s)F nh~**oo |Re,VaeR h@:( ZdAA[ 4[4uo?M= *qCf K4KgV4]C1 =) pl[8Pzlx Q+~.

Please login or register for full access


Already registered?  Login

Chat with BeiGene